Management of Relapsed and Refractory Hodgkin Lymphoma in 2018

被引：2

作者：

Rutherford, Sarah C. ^{[1
]}

Leonard, John P. ^{[1
]}

机构：

[1] Weill Cornell Med, New York Presbyterian Hosp, Weill Dept Med, Meyer Canc Ctr,Div Hematol & Med Oncol, 1305 York Ave,7th Floor, New York, NY 10021 USA

来源：

JAMA ONCOLOGY | 2018年 / 4卷 / 08期

关键词：

STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; NIVOLUMAB; TRIAL; MULTICOHORT; THERAPY; FAILURE;

D O I：

10.1001/jamaoncol.2018.1767

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1120 / 1121

页数：2

共 50 条

[1] Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma
Gordon, Leo I.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (5.5): : 716 - 718
[2] Refractory or relapsed Hodgkin lymphoma
Connors, J
ANNALS OF ONCOLOGY, 2005, 16 : 40 - 40
[3] Relapsed/refractory Hodgkin lymphoma
Sheikh, Semira
Kuruvilla, John
HEMASPHERE, 2018, 2 : 71 - 74
[4] Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents
Daw, Stephen
Wynn, Rob
Wallace, Hamish
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (03) : 249 - 260
[5] Therapy of relapsed and refractory Hodgkin Lymphoma
von Tresckow, B.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 62 - 62
[6] Managing relapsed and refractory Hodgkin lymphoma
Brice, Pauline
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (01) : 3 - 13
[7] Pembrolizumab for relapsed or refractory Hodgkin lymphoma
Pulsoni, Alessandro
LANCET ONCOLOGY, 2020, 22 (06): : E234 - E234
[8] Relapsed/Refractory Classical Hodgkin Lymphoma
Winter, Jane N.
TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 : 34 - 35
[9] Treatment of Relapsed/Refractory Hodgkin Lymphoma
Chen, Robert W.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (02) : 6 - 9
[10] Treatment of relapsed and refractory Hodgkin Lymphoma
von Tresckow, Bastian
Moskowitz, Craig H.
SEMINARS IN HEMATOLOGY, 2016, 53 (03) : 180 - 185

← 1 2 3 4 5 →